HOUSTON – April 16, 2019 – The Kidney Cancer Association (KCA) is pleased to announce its Board of Directors recently approved $1.3 million in new grant funding to advance early detection and new treatments for kidney cancer. The application process opens on April 17 and closes on May 20. Award winners will be announced in the Fall of 2019.
“The KCA Board of Directors is committed to providing research funding with the goal of identifying new treatments and finding new ways to prevent and manage the disease,” said Christopher Wood, Board President. “With these advancements in research and a greater understanding of these cancers, we believe the outcomes of these grants will have substantive impact for kidney cancer patients.”
Six grants are divided among two distinct awards – the Advanced Discovery Awards (ADA), two $500,000 grants for established investigators, and four $75,000 Young Investigator Awards (YIA).
The purpose of establishing the new ADA is to promote the collaboration between a clinician including a urologic oncologist, medical oncologist or radiation oncologist and a Ph.D., to propose new research that will make an immediate impact in the field of kidney cancer. Research may include biomarker development, development of novel therapeutic targets, correlative studies associated with ongoing or completed clinical trials, or assays that promote the early detection of kidney cancer.
The YIA seeks to encourage promising researchers in the areas of urology and clinical oncology who are planning to pursue an investigative career in kidney cancer. To qualify, applicants must have achieved a post-graduate degree or doctoral degree and currently be in the last two years of their final subspecialty training at an academic medical institution (a single entity medical school and university hospital) at the time of their application. The KCA has increased the amounts of the YIA from $50,000 to $75,000, and increased the number of grants from two to four to encourage more of these rising stars in this field.
All grant proposals will be evaluated through the Letter of Intent (LOI) Process. An independent panel of reviewers, who are recognized experts in the field, will conduct a blinded, scored review of all applications received.
Founded in 1990 by a group of physicians and patients at the University of Chicago and Northwestern, many of whom are still active in the organization today, the KCA’s mission is bringing an end to death and suffering from renal cancers and envisioning a world without kidney cancer.
The KCA is a recognized and respected thought leader on the topic of kidney cancer in the medical community and a trusted resource for patients navigating the disease. As an international organization, the KCA unites patients, families, doctors, researchers and other health professionals from around the world who are focused on education, resesarch, and advocacy – all in an effort to promote the work necessary to understand, prevent and treat kidney cancer.